Which has stronger valuation & earnings, HURA or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is HURA or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Candel Therapeutics N/A -60.42% -41.33%

Is OCS or HURA more profitable?

TuHURA Biosciences has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% TuHURA Biosciences N/A -156.12% -105.38%

Which has stronger earnings & valuation, DRUG or HURA?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A

Is DRUG or HURA more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -20.58% -20.25% TuHURA Biosciences N/A -156.12% -105.38%

TuHURA Biosciences (HURA) Competitors

$2.52 -0.12 (-4.55%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$2.55 +0.03 (+1.23%)

As of 06/24/2026 07:34 PM Eastern

Compare

HURA vs. ACRS, CADL, OCS, DRUG, and AQST

Should you buy TuHURA Biosciences stock or one of its competitors? MarketBeat compares TuHURA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TuHURA Biosciences include Aclaris Therapeutics (ACRS), Candel Therapeutics (CADL), Oculis (OCS), Bright Minds Biosciences (DRUG), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry.

How does TuHURA Biosciences compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Aclaris Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

TuHURA Biosciences has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
TuHURA Biosciences	N/A	-156.12%	-105.38%

Aclaris Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 140.08%. TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 257.14%. Given TuHURA Biosciences' higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

TuHURA Biosciences has lower revenue, but higher earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	85.44	-$64.92M	-$0.56	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Aclaris Therapeutics had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 3 mentions for Aclaris Therapeutics and 0 mentions for TuHURA Biosciences. Aclaris Therapeutics' average media sentiment score of 0.36 beat TuHURA Biosciences' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aclaris Therapeutics	Neutral
TuHURA Biosciences	Neutral

Summary

Aclaris Therapeutics beats TuHURA Biosciences on 11 of the 16 factors compared between the two stocks.

How does TuHURA Biosciences compare to Candel Therapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

TuHURA Biosciences has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, meaning that its stock price is 149% less volatile than the broader market.

Candel Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Candel Therapeutics had 2 more articles in the media than TuHURA Biosciences. MarketBeat recorded 2 mentions for Candel Therapeutics and 0 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.00 equaled Candel Therapeutics'average media sentiment score.

Company	Overall Sentiment
TuHURA Biosciences	Neutral
Candel Therapeutics	Neutral

TuHURA Biosciences currently has a consensus target price of $9.00, indicating a potential upside of 257.14%. Candel Therapeutics has a consensus target price of $18.00, indicating a potential upside of 94.17%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Candel Therapeutics' return on equity of -60.42% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Candel Therapeutics	N/A	-60.42%	-41.33%

Summary

TuHURA Biosciences and Candel Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does TuHURA Biosciences compare to Oculis?

Oculis (NASDAQ:OCS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Oculis had 2 more articles in the media than TuHURA Biosciences. MarketBeat recorded 2 mentions for Oculis and 0 mentions for TuHURA Biosciences. Oculis' average media sentiment score of 0.00 equaled TuHURA Biosciences'average media sentiment score.

Company	Overall Sentiment
Oculis	Neutral
TuHURA Biosciences	Neutral

Oculis has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

TuHURA Biosciences has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	462.24	-$119.44M	-$2.13	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

TuHURA Biosciences has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
TuHURA Biosciences	N/A	-156.12%	-105.38%

Oculis currently has a consensus target price of $38.33, suggesting a potential upside of 231.60%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 257.14%. Given TuHURA Biosciences' higher probable upside, analysts clearly believe TuHURA Biosciences is more favorable than Oculis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

22.3% of Oculis shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Oculis beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Bright Minds Biosciences?

Bright Minds Biosciences (NASDAQ:DRUG) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Bright Minds Biosciences has a beta of -5.53, suggesting that its stock price is 653% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

Bright Minds Biosciences' return on equity of -20.58% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-20.58%	-20.25%
TuHURA Biosciences	N/A	-156.12%	-105.38%

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Bright Minds Biosciences' average media sentiment score of 0.00 equaled TuHURA Biosciences'average media sentiment score.

Company	Overall Sentiment
Bright Minds Biosciences	Neutral
TuHURA Biosciences	Neutral

Bright Minds Biosciences currently has a consensus price target of $143.83, suggesting a potential upside of 117.21%. TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 257.14%. Given TuHURA Biosciences' higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Bright Minds Biosciences beats TuHURA Biosciences on 7 of the 11 factors compared between the two stocks.

How does TuHURA Biosciences compare to Aquestive Therapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

TuHURA Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 257.14%. Aquestive Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 70.17%. Given TuHURA Biosciences' higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 0.2% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TuHURA Biosciences has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

In the previous week, Aquestive Therapeutics had 4 more articles in the media than TuHURA Biosciences. MarketBeat recorded 4 mentions for Aquestive Therapeutics and 0 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.00 equaled Aquestive Therapeutics'average media sentiment score.

Company	Overall Sentiment
TuHURA Biosciences	Neutral
Aquestive Therapeutics	Neutral

TuHURA Biosciences has higher earnings, but lower revenue than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Aquestive Therapeutics	$44.54M	14.07	-$83.78M	-$0.61	N/A

TuHURA Biosciences has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Aquestive Therapeutics' return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Summary

Aquestive Therapeutics beats TuHURA Biosciences on 9 of the 14 factors compared between the two stocks.

Get TuHURA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HURA vs. The Competition

Export

Metric	TuHURA Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$168.12M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-4.13	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	7.41	8.26	10.76	6.41
Net Income	-$30.05M	$23.91M	$3.56B	$337.14M
7 Day Performance	-1.95%	2.12%	0.98%	-1.06%
1 Month Performance	0.80%	2.40%	0.78%	0.49%
1 Year Performance	13.00%	57.09%	30.24%	28.43%

TuHURA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HURA TuHURA Biosciences	1.5644 of 5 stars	$2.52 -4.5%	$9.00 +257.1%	+7.2%	$168.12M	N/A	N/A	N/A	Gap Down
ACRS Aclaris Therapeutics	3.0453 of 5 stars	$4.88 +0.8%	$11.50 +135.7%	+215.1%	$678.21M	$8.37M	N/A	100
CADL Candel Therapeutics	2.016 of 5 stars	$9.14 -0.1%	$18.00 +97.0%	+91.1%	$672.33M	N/A	N/A	60	News Coverage
OCS Oculis	2.8305 of 5 stars	$11.52 -1.3%	$38.33 +232.7%	-41.5%	$668.22M	$1.45M	N/A	2
DRUG Bright Minds Biosciences	2.3007 of 5 stars	$65.23 +7.5%	$143.83 +120.5%	+136.5%	$633.85M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HURA) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TuHURA Biosciences (HURA) Competitors

HURA vs. ACRS, CADL, OCS, DRUG, and AQST

How does TuHURA Biosciences compare to Aclaris Therapeutics?

Summary

How does TuHURA Biosciences compare to Candel Therapeutics?

Summary

How does TuHURA Biosciences compare to Oculis?

Summary

How does TuHURA Biosciences compare to Bright Minds Biosciences?

Summary

How does TuHURA Biosciences compare to Aquestive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TuHURA Biosciences (HURA) Competitors

HURA vs. ACRS, CADL, OCS, DRUG, and AQST

How does TuHURA Biosciences compare to Aclaris Therapeutics?

Which has more risk & volatility, ACRS or HURA?

Is ACRS or HURA more profitable?

Do analysts recommend ACRS or HURA?

Which has better valuation and earnings, ACRS or HURA?

Do institutionals & insiders hold more shares of ACRS or HURA?

Does the media refer more to ACRS or HURA?

Summary

How does TuHURA Biosciences compare to Candel Therapeutics?

Which has more volatility & risk, HURA or CADL?

Which has stronger valuation & earnings, HURA or CADL?

Do insiders & institutionals believe in HURA or CADL?

Does the media favor HURA or CADL?

Do analysts recommend HURA or CADL?

Is HURA or CADL more profitable?

Summary

How does TuHURA Biosciences compare to Oculis?

Does the media prefer OCS or HURA?

Which has more risk and volatility, OCS or HURA?

Which has preferable valuation and earnings, OCS or HURA?

Is OCS or HURA more profitable?

Do analysts recommend OCS or HURA?

Do institutionals and insiders have more ownership in OCS or HURA?

Summary

How does TuHURA Biosciences compare to Bright Minds Biosciences?

Which has stronger earnings & valuation, DRUG or HURA?

Which has more volatility and risk, DRUG or HURA?

Is DRUG or HURA more profitable?

Do institutionals & insiders have more ownership in DRUG or HURA?

Does the media prefer DRUG or HURA?

Do analysts recommend DRUG or HURA?

Summary

How does TuHURA Biosciences compare to Aquestive Therapeutics?

Do analysts recommend HURA or AQST?

Do insiders & institutionals have more ownership in HURA or AQST?

Which has more volatility & risk, HURA or AQST?

Does the media prefer HURA or AQST?

Which has better valuation & earnings, HURA or AQST?

Is HURA or AQST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools